+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Capecitabine Market - Global Forecast 2026-2032- Product Image
Capecitabine Market - Global Forecast 2026-2032- Product Image
New

Capecitabine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010660
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The capecitabine market is entering a new era of complexity and growth, propelled by significant advances in oncology care, regulatory policies, and evolving distribution models. For senior decision-makers, staying ahead requires a careful understanding of the mechanisms and strategic implications defining this dynamic environment.

Market Snapshot: Capecitabine Market Size and Growth

The capecitabine market grew from USD 473.19 million in 2025 to USD 505.99 million in 2026. It is expected to continue growing at a CAGR of 6.39%, reaching USD 730.22 million by 2032. This trajectory underscores robust demand for oral antimetabolite therapies across multiple solid tumor indications and highlights shifting patterns in outpatient cancer treatment and supply chain management.

Scope & Segmentation

  • Indications: Breast Cancer, Colorectal Cancer (delineated into Colon and Rectal Cancer), Gastric Cancer, and Pancreatic Cancer. Market differentiation is strongly influenced by the unique efficacy and tolerability profiles across these tumor types, alongside distinctions in adjuvant versus metastatic treatment approaches.
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy. Each channel shapes patient access, prescription fulfillment, and reimbursement frameworks, impacting treatment continuity and patient support services.
  • End User Settings: Cancer Research Institutes, Clinics, Homecare Settings, and Hospitals. The rise of homecare and decentralized models is enabled by the oral administration route, supporting patient-centric delivery and shifting resource demands.
  • Dosage Strengths: 150 Mg and 500 Mg. Available strengths allow for regimen flexibility, dosing accuracy, and tailored packaging solutions.
  • Formulation Types: Tablet and Extended Release Tablet. Modified-release profiles represent opportunities to enhance tolerability and dosing convenience for diverse patient populations.
  • Therapy Regimens: Combination Therapy and Monotherapy. Strategic use of capecitabine in combination regimens reflects evolving best practices in systemic cancer control and pharmacovigilance.
  • Packaging Options: Blister Pack and Bottle. Packaging choices directly support safety labeling, logistics, and adherence interventions.
  • Geographies Covered: Americas, Europe Middle East & Africa, and Asia-Pacific. Regional dynamics shape regulatory access, market entry, and operational resilience strategies.

Key Takeaways for Capecitabine Market Strategy

  • The shift toward oral oncology therapies is transforming cancer care pathways and outpatient delivery models, supporting both clinical efficiency and patient autonomy.
  • Multidisciplinary integration, including interplay with surgery, radiation, and supportive care, is expanding the role of capecitabine in oncologic protocols.
  • Regulatory innovation and payer focus on value-based outcomes are accelerating adoption of capecitabine in new indications, driven by advances in genomic profiling and toxicity management.
  • Robust supply chain management, including serialization and digital logistics, is increasingly essential to ensuring reliability and supporting decentralized care delivery.
  • Strategic alliances between manufacturers, distributors, and specialty pharmacies are reducing access barriers, supporting adherence monitoring, and aligning commercial tactics with evolving market dynamics.

Tariff Impact: United States Procurement and Supply Chain Adaptations

Tariffs introduced and escalated in the United States through 2025 have driven market participants to reassess sourcing strategies and production footprints. Pharmaceutical suppliers and distributors are negotiating longer-term agreements and diversifying procurement to cushion tariff-related fluctuations. As a result, hospital pharmacies, specialty distributors, and ambulatory providers are enhancing their inventory management to sustain uninterrupted therapy delivery. Tariff volatility has increased the emphasis on supply resilience, fostering contractual flexibility and transparent cost analysis as critical components in formulary and procurement decisions.

Methodology & Data Sources

This market assessment adopts a triangulated research approach, combining structured interviews with clinical, procurement, and distribution experts, along with reviews of peer-reviewed literature, regulatory guidelines, and clinical practice frameworks. Analytical methods include qualitative thematic analysis, comparative policy review, and scenario-based assessments to evaluate the impact of regulatory and supply chain trends.

Why This Report Matters

  • Equips decision-makers with actionable insights to navigate evolving regulatory, clinical, and supply-chain complexities in the capecitabine market.
  • Highlights strategic opportunities to align product stewardship, supply resilience, and payer engagement with operational and patient-centered priorities.
  • Provides clarity on regional adaptation strategies and the future of decentralized oncology therapeutics delivery, supporting sustainable commercial and clinical planning.

Conclusion

The evolving capecitabine market demands coordinated responses from all industry stakeholders. Forward-looking strategies, investment in robust supply chains, and proactive collaboration will determine successful market access and ongoing patient benefit from oral oncology therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Capecitabine Market, by Indication
8.1. Breast Cancer
8.2. Colorectal Cancer
8.2.1. Colon Cancer
8.2.2. Rectal Cancer
8.3. Gastric Cancer
8.4. Pancreatic Cancer
9. Capecitabine Market, by Dosage Strength
9.1. 150 Mg
9.2. 500 Mg
10. Capecitabine Market, by Therapy Regimen
10.1. Combination Therapy
10.2. Monotherapy
11. Capecitabine Market, by Packaging
11.1. Blister Pack
11.2. Bottle
12. Capecitabine Market, by End User
12.1. Cancer Research Institutes
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
13. Capecitabine Market, by Distribution Channel
13.1. Hospital Pharmacy
13.2. Online Pharmacy
13.3. Retail Pharmacy
14. Capecitabine Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Capecitabine Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Capecitabine Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Capecitabine Market
18. China Capecitabine Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Accord Healthcare
19.6. Alkem Laboratories Ltd.
19.7. Bayer AG
19.8. Celon Laboratories Ltd.
19.9. Cipla Ltd.
19.10. Dr. Reddy's Laboratories
19.11. Eli Lilly and Company
19.12. F. Hoffmann-La Roche Ltd. (Genentech)
19.13. Hetero Labs Ltd.
19.14. Intas Pharmaceuticals
19.15. Lexicare Pharma Pvt. Ltd.
19.16. MSN Laboratories
19.17. Mylan N.V.
19.18. Novartis AG
19.19. Pfizer Inc.
19.20. Shilpa Medicare Ltd.
19.21. Sun Pharmaceutical Industries Ltd.
19.22. Taj Pharmaceuticals
19.23. Teva Pharmaceutical Industries Ltd.
19.24. Torrent Pharmaceuticals Ltd.
List of Figures
FIGURE 1. GLOBAL CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CAPECITABINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CAPECITABINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CAPECITABINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CAPECITABINE MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CAPECITABINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CAPECITABINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CAPECITABINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CAPECITABINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CAPECITABINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CAPECITABINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CAPECITABINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CAPECITABINE MARKET SIZE, BY COLON CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CAPECITABINE MARKET SIZE, BY COLON CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CAPECITABINE MARKET SIZE, BY COLON CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CAPECITABINE MARKET SIZE, BY RECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CAPECITABINE MARKET SIZE, BY RECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CAPECITABINE MARKET SIZE, BY RECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CAPECITABINE MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CAPECITABINE MARKET SIZE, BY GASTRIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CAPECITABINE MARKET SIZE, BY GASTRIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CAPECITABINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CAPECITABINE MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CAPECITABINE MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CAPECITABINE MARKET SIZE, BY 150 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CAPECITABINE MARKET SIZE, BY 150 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CAPECITABINE MARKET SIZE, BY 150 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CAPECITABINE MARKET SIZE, BY 500 MG, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CAPECITABINE MARKET SIZE, BY 500 MG, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CAPECITABINE MARKET SIZE, BY 500 MG, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CAPECITABINE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CAPECITABINE MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CAPECITABINE MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CAPECITABINE MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CAPECITABINE MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CAPECITABINE MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CAPECITABINE MARKET SIZE, BY BLISTER PACK, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CAPECITABINE MARKET SIZE, BY BLISTER PACK, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CAPECITABINE MARKET SIZE, BY BLISTER PACK, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CAPECITABINE MARKET SIZE, BY BOTTLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CAPECITABINE MARKET SIZE, BY BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CAPECITABINE MARKET SIZE, BY BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CAPECITABINE MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CAPECITABINE MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CAPECITABINE MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CAPECITABINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CAPECITABINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CAPECITABINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CAPECITABINE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CAPECITABINE MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CAPECITABINE MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CAPECITABINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CAPECITABINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CAPECITABINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CAPECITABINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CAPECITABINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CAPECITABINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CAPECITABINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CAPECITABINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS CAPECITABINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 99. EUROPE CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 102. EUROPE CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 103. EUROPE CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 104. EUROPE CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 105. EUROPE CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. AFRICA CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. AFRICA CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. AFRICA CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 118. AFRICA CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 119. AFRICA CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 120. AFRICA CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 121. AFRICA CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. AFRICA CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CAPECITABINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASEAN CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 134. ASEAN CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 135. ASEAN CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 136. ASEAN CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 137. ASEAN CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 138. ASEAN CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. ASEAN CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. GCC CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GCC CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. GCC CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 143. GCC CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 144. GCC CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 145. GCC CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 146. GCC CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. GCC CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 156. BRICS CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. BRICS CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 158. BRICS CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 159. BRICS CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 160. BRICS CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 161. BRICS CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 162. BRICS CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. BRICS CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. G7 CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. G7 CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. G7 CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 167. G7 CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 168. G7 CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 169. G7 CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 170. G7 CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. G7 CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. NATO CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. NATO CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 174. NATO CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 175. NATO CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 176. NATO CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 177. NATO CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 178. NATO CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. NATO CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL CAPECITABINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 186. UNITED STATES CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 189. CHINA CAPECITABINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. CHINA CAPECITABINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 191. CHINA CAPECITABINE MARKET SIZE, BY COLORECTAL CANCER, 2018-2032 (USD MILLION)
TABLE 192. CHINA CAPECITABINE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 193. CHINA CAPECITABINE MARKET SIZE, BY THERAPY REGIMEN, 2018-2032 (USD MILLION)
TABLE 194. CHINA CAPECITABINE MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
TABLE 195. CHINA CAPECITABINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. CHINA CAPECITABINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Capecitabine market report include:
  • Accord Healthcare
  • Alkem Laboratories Ltd.
  • Bayer AG
  • Celon Laboratories Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd. (Genentech)
  • Hetero Labs Ltd.
  • Intas Pharmaceuticals
  • Lexicare Pharma Pvt. Ltd.
  • MSN Laboratories
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Shilpa Medicare Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 505.99 Million
Forecasted Market Value ( USD ) by 2032 $ 730.22 Million
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Oral Capecitabine Market - Global Forecast 2025-2030 - Product Image

Oral Capecitabine Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Capecitabine Tablets Market - Global Forecast 2025-2030 - Product Image

Capecitabine Tablets Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Capecitabine Market Report 2025 - Product Image

Capecitabine Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Capecitabine - Global Strategic Business Report - Product Image

Capecitabine - Global Strategic Business Report

  • Report
  • 220 Pages
  • Global
From
Capecitabine (CAS 154361-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Capecitabine (CAS 154361-50-9) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From

About the Capecitabine Market

Capecitabine is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of oral chemotherapy, meaning it is taken in pill form. Capecitabine works by blocking the growth of cancer cells and preventing them from dividing and spreading. It is often used in combination with other chemotherapy drugs to increase the effectiveness of treatment. Capecitabine is generally well-tolerated, with fewer side effects than other chemotherapy drugs. Capecitabine is a relatively new drug, first approved by the FDA in 1998. It is now widely used in the treatment of NSCLC, and is often prescribed in combination with other chemotherapy drugs. It is also used to treat other types of cancer, such as breast cancer and colorectal cancer. In the Capecitabine market, some of the major players include Roche, Pfizer, Merck, AstraZeneca, and Bristol-Myers Squibb. These companies manufacture and distribute the drug, as well as provide support services to healthcare providers and patients. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.